After mulling its options for three months, Human Genome Sciences Inc. accepted a sweetened proposal from GlaxoSmithKline plc, agreeing to a union that most industry observers expected all along. Read More
The FDA approved Gilead Sciences Inc.'s Truvada as the first drug to help reduce the risk of contracting HIV-1, the most common form of HIV infection. Read More
Juventas Therapeutics Inc., of Cleveland, is funded through the end Phase II trials for its biologic product, JVS-100, now that it has closed a $22.2 million Series B financing round co-led by Triathlon Medical Venture Partners and New Science Ventures. Read More
DUBLIN, Ireland – As a general science meeting, the Euroscience Open Forum (ESOF) does a pretty good job of being all things to all men and all women. Read More
• Horizon Discovery Ltd., of Cambridge, UK, said it has established a Center of Excellence for gene editing at the University of Leicester, UK. The program will focus on the creation of isogenic cell lines that contain "risk" or "protective" SNPs associated with cardiovascular disease, identified from genomewide association studies. Read More
• Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported that an investigator-sponsored trial of its monocolonal antibody bavituximab for patients with Stage II or Stage III rectal adenocarcinoma has been initiated. The open-label Phase I trial will enroll up to 18 patients to receive the antibody in combination with capcitabine and radiation for eight weeks. Read More
